<DOC>
	<DOCNO>NCT02767531</DOCNO>
	<brief_summary>Patients Type I Hyperlipoproteinemia ( T1HLP ) rare form hypertriglyceridemia mark significant chylomicronemia recurrent episode acute pancreatitis . T1HLP cause deficiency lipoprotein lipase one cofactor . Many patient challenge treat , effective therapy available extremely low fat diet . This diet exceedingly difficult follow , despite adherence , many patient still chylomicronemia develop acute pancreatitis . Specific Aim : To determine efficacy gastric pancreatic lipase inhibitor , Orlistat , reduce serum triglyceride level patient T1HLP .</brief_summary>
	<brief_title>Orlistat Treatment Type I Hyperlipoproteinemia</brief_title>
	<detailed_description>Type I hyperlipoproteinemia rare , autosomal recessive metabolic disorder characterize extreme hypertriglyceridemia due deficiency lipoprotein lipase related protein . Treatment patient challenge triglyceride-lowering medication ineffective . A low fat diet helpful , however , despite good dietary compliance , patient continue severe hypertriglyceridemia recurrent pancreatitis life threaten . Therefore , Investigator wish investigate whether induce dietary fat malabsorption inhibit chylomicron formation cause lower serum triglyceride ( TG ) beyond effect limit dietary fat intake . Investigator study efficacy safety inhibitor intestinal lipase ( Orlistat ) reduce serum triglyceride level patient Type I hyperlipoproteinemia . Investigator plan enroll 20 patient Type I hyperlipoproteinemia randomize , double-blind , placebo-controlled , cross-over trial . During last week study period , fast blood sample draw three consecutive day serum lipids chemistry panel . The primary endpoint serum triglyceride ; secondary endpoint variable fast postprandial serum chylomicron-TG level , postprandial serum TG level meal tolerance test retinyl palmitate level meal tolerance test . Repeated measure analysis variance use statistical comparison . These result may help design novel therapeutic approach patient Type 1 hyperlipoproteinemia .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>1 . Type I hyperlipoproteinemia 2 . Fasting serum triglyceride level great 1000 mg/dL 3 . Age &gt; 8 year 1 . Secondary hypertriglyceridemias due diabetes , renal disease , hypothyroidism , alcoholism drug therapy estrogens estrogen analogue , steroid , HIVprotease inhibitor , retinoic acid derivative interferon 2 . Pregnant lactate woman 3 . Significant liver disease ( elevated transaminase &gt; 2 time upper limit normal ) Alcohol abuse ( &gt; 7 drink 84 g per week woman &gt; 14 drink 168 g per week men ) 4 . Severe anemia ( hematocrit &lt; 24 % ) 5 . Drug use ( cocaine , marijuana , LSD , etc . ) 6 . Major surgery past three month 7 . Congestive heart failure 8 . Serum creatinine great 2.5 mg/dL 9 . Cancer within past five year 10 . Gastrointestinal surgery past 11 . Current therapy anticoagulant , digoxin , antiarrhythmic 12 . Current therapy cyclosporine 13 . Chronic malabsorption syndromes 14 . Cholestasis 15 . Acute illness acute pancreatitis last 8 week</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>